Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JL15003
- Development stage
- Phase 2
- Lead developer
- Jecho Biopharmaceuticals
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intratumoral
01
Overview
JL15003 is an investigational oncolytic virus therapy developed by Jecho Biopharmaceuticals for the treatment of recurrent or relapsed glioblastoma multiforme (GBM). As a Category 1 therapeutic biological drug, it is designed for administration via a single intratumoral injection. The therapy works by selectively infecting and replicating within malignant glioma cells, leading to direct tumor cell lysis. This oncolytic process is intended to release tumor-associated antigens and damage-associated molecular patterns, which may subsequently stimulate a localized and systemic anti-tumor immune response. JL15003 is currently being evaluated in Phase I clinical trials to assess its safety, tolerability, viral shedding, and preliminary efficacy in adult patients with recurrent glioblastoma.
- Other names
- JL15003 InjectionJL-15003 InjectionJL 15003 Injection
Beyond the preview
Go deeper on JL15003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JL15003.